Search PubMed⌕ Search

Biomedical subjects

P R Huber

Publications and source records attributed to P R Huber.

At least 37 records · Page 2Linked to original sources
PubMed1984

[Contraceptive effect of low-dosage ovulation inhibitors containing various progestagen agents].

The decrease of steroid dosage in oral contraceptives resulted in a decrease of serious side effects with continued effectiveness. However, a increase in subjectively disturbing bleeding abnormalities occurred at the same time. The development of triphasic preparations was designed to eliminate these abnormal bleeding episodes by stepwise changes of the estrogen and progestagen doses. Compared to the low dosage combination preparation, triphasic preparations show often a persistence of insufficiently suppressed hormone levels in single determinations but not in mean averages of determinations. This could be an explanation for the reported pregnancies. In spite of these results, the literature reports rare failures during the administration of the triphasic preparations and additional factors could determine the contraceptive effectiveness.

Adolescent↗
PubMed1983

Tissue polypeptide antigen (TPA) and prostatic acid phosphatase in serum of prostatic cancer patients.

Tissue polypeptide antigen (TPA) and prostatic acid phosphatase were both detected by radioimmunoassay in the sera of a male population (age greater than 45 years) consulting the clinic for urological problems or check-up on treatment. Increased concentrations of TPA were associated mostly with advanced stages of prostatic carcinomas, parallel to PAP. Some enhanced TPA concentrations were detected with haematuria and adenomas of the prostate.

Acid Phosphatase↗
PubMed1982

Creatine kinase isoenzyme (CK-BB) in combination to prostatic acid phosphatase measured by RIA in the diagnosis of prostatic cancer.

Creatine kinase isoenzyme (CK-BB) measured by mass was used to determine its value in the early diagnosis of prostatic cancer. Sera of patients with prostatic carcinoma of various stages (treated and untreated) were compared to normal male sera and sera of patients with benign hyperplasia of the prostate (BPH) with respect to CK-BB. The sera were simultaneously tested for PAP content. The sensitivity of the CK-BB-RIA was 1.63 +/- 0.08 microgram/1 and reproducibility in the higher and lower concentration range 7.6% and 10.5%, respectively. CK-BB alone or in combination with PAP is no marker for early detection of prostatic cancer. In individual cases changes occurred similar to those found with a malignant growth of the prostate.

Acid Phosphatase↗
PubMed1982

Measurement of prostatic acid phosphatase in serum and bone marrow: radioimmunoassay and enzymic measurement compared.

We quantitated the concentrations of prostatic acid phosphatases (EC 3.1.3.2) in serum and bone-marrow aspirates with three commercial radioimmunoassay kits, and the catalytic activities with a thymolphthalein monophosphate-based enzyme test. The enzyme's immunological activity in serum was compared with its catalytic activity for its potential as a detector of early prostatic cancer and its performance as an early marker of metastatic activity in bone. Neither measurement is useful for detecting early stages of prostatic cancer. The spread of carcinoma to lymph nodes or to bone is detected with greater frequency by radioimmunoassay than by the enzymic test. Radioimmunoassay also detected metastasis to the bone more frequently than did physical methods. Analytical and clinical performance of the four methods is described.

Acid Phosphatase↗
PubMed1981

[Current assessment of radioimmunological determination (RIA) of prostate acid phosphatase in the diagnosis of prostatic cancer].

Sera of patients without any tumors of the prostate and sera of patients with benign and malignant tumors of the prostate were tested with the enzyme assay using thymolphthalein monophosphate as substrate. The results were compared with the RIA of Clinical Assay (Travenol) and found to yield an approximately 50% better recognition of malignant growth. However, false-positive rates were rather high (approximately 20%), which lowers the overall success rate to approximately 30%.

Acid Phosphatase↗
PubMed1980

Quantitative estimation of cellular retinoic acid-binding protein activity in normal, dysplastic, and neoplastic human breast tissue.

A technique for reproduction and quantitative determination of human cellular retinoic acid-binding protein (CRABP) activity in breast tissue specimens is described. A multiphasic polyacrylamide disc gel electrophoresis system (operative at pH 10.2) was adapted for this purpose. This technique allows, after incubation with tritiated retinoic acid (RA) overnight, the separation of the specific CRABP activity from the nonspecific serum-originated binding activity and from the free RA. Previous purification of the tissue cytosols is therefore not necessary. The same assay method was also used for the determination of the molecular weight (Ferguson plot, m.w. 13,000) and the dissociation constant Kd (2.5 x 10(-7) M) of mammary CRABP. The activity in tissue cytosol, stored at -70 degrees, was found to be stable for at least 3 months. Results from 88 breast tissue specimens of different pathological degree are presented. CRABP activity was found in all tissue categories with progressively increasing amounts from normal tissue to breast cancer. The activity in the cancer tissues (14.85 +/- 12.05 pmol RA bound per mg soluble protein: N = 27) was significantly different (p less than 0.001) from the activity determined in tissue with simple dysplasia without epithelial proliferation [4.3 +/- 2.2 (S.D.) pmol RA bound per mg protein; N = 30]. It is possible that in the cases where high amounts of CRABP activity are found in dysplastic and preneoplastic tissue, a high risk for breast cancer development exists. Therefore, CRABP is tentatively proposed as a dedifferentiation and/or proliferation marker.

Adolescent↗
PubMed1978

Retinoic acid-binding protein in human breast cancer and dysplasia.

Seventy-five specimens of human breast tissue were checked for the presence of cellular retinoic acid-binding protein (cRABP). Fifty-two percent of the primary carcinomas and 43% of the dysplastic breast lesions (stage MII) contained detectable amounts of crabp, whereas no cRABP was found in normal tissue. Sucrose gradient centrifugation and electrophoresis on agarose were used for analysis of the presence of cRABP. The cRABP of human origin (normal uterus and neoplastic mammary tissue) differed in its mobility in agarose electrophoresis from that of rat testis cRABP.

Animals↗